Report : North America Antibody Discovery Market Forecast to 2030 - Regional Analysis - by Antibody Type (Monoclonal Antibodies, Polyclonal Antibodies, and Others), Nature (Human and Humanized, Chimeric, and Murine), Services (Phage Display, Hybridoma, Transgenic Animal, Single Cell, and Yeast Display), and End User (Pharmaceutical and Biotechnology Companies, Research Laboratories, and Others)
At 6.8% CAGR, North America Antibody Discovery Market is Projected to be Worth US$ 22,01,692.41 Million by 2030, says Business Market Insights
According to Business Market Insights' research, the North America antibody discovery market was valued at US$ 12,98,237.57 million in 2022 and is expected to reach US$ 22,01,692.41 million by 2030, registering a CAGR of 6.8% from 2022 to 2030. Developments for custom antibodies and proliferation of biotechnology industry in developing regions are among the critical factors attributed to drive the North America antibody discovery market growth.
Antibodies are indispensable research tools that enable researchers in various scientific fields to specify, identify, localize, and quantify their protein targets. Advancements in medical technologies provide support for faster and highly efficient discoveries of antibodies that are customized as per the customers' requirements. Integrating bioinformatics in the discovery of antibodies has triggered improvements in custom antibody research. Artificial intelligence (AI) has the potential to emerge as an essential, value addition tool in the discovery of custom antibodies. AI and machine learning (ML) algorithms analyze large data sets, predict antibody-antigen interactions, and optimize antibody properties. These techniques can also aid in design, screening, and lead optimization; identify patterns; predict binding affinities; and prioritize antibody candidates for further characterization. The use of AI and ML is driven by the growing availability of big data analytics solutions and advancements in computing power, in addition to the need to efficiently analyze and interpret large-scale antibody screening data. The integration of AI and ML technologies has the potential to improve the success rates of antibody discovery projects and facilitate the development of more effective therapeutic antibodies.
The use of custom monoclonal antibodies is an attractive area in oncology research. Most of the clinical trials are performed using monoclonal antibodies derived from rabbits. For instance, anti-VEGF, a humanized anti-vascular growth endothelial factor (rabbit mAb), is currently under clinical studies for the evaluation of its effects on metastatic colorectal cancer and other solid tumors. Likewise, anti-VEGF is under clinical studies for its use in treating age-related macular degeneration. Monoclonal antibodies derived from rabbits are proven as a superior alternative to mouse-derived monoclonal antibodies due to the presence of a larger complementarity-determining region (CDR) in the antigen-binding site. In addition, monoclonal antibodies can be used to produce higher affinity clones. For instance, Creative Biolabs offers various custom polyclonal and monoclonal antibody production services, from gene expression or peptide synthesis to antibody purification and labeling. Therefore, custom monoclonal antibodies are likely to emerge as a profitable trend in the antibody discovery market during the forecast period.
On the contrary, high cost of production hampers the growth of North America antibody discovery market.
Based on antibody type, the North America antibody discovery market is segmented into monoclonal antibodies, polyclonal antibodies, and others. The monoclonal antibodies segment held 81.4% market share in 2022, amassing US$ 1,056.84 billion. It is projected to garner US$ 1,832.01 billion by 2030 to register 7.1% CAGR during 2022-2030.
In terms of nature, the North America antibody discovery market is segmented into human and humanized, chimeric, and murine. The human and humanized segment held 56.6% share of North America antibody discovery market in 2022, amassing US$ 734.75 billion. It is anticipated to garner US$ 1,289.28 billion by 2030 to expand at 7.3% CAGR during 2022-2030.
By services, the North America antibody discovery market is divided into phage display, hybridoma, transgenic animal, single cell, and yeast display. The phage display segment held 35.2% share of North America antibody discovery market in 2022, amassing US$ 457.56 billion. It is projected to garner US$ 816.06 billion by 2030 to expand at 7.5% CAGR from 2022 to 2030.
Based on end user, the North America antibody discovery market is categorized into pharmaceutical and biotechnology companies, research laboratories, and others. The pharmaceutical and biotechnology companies segment held 53.3% share of North America antibody discovery market in 2022, amassing US$ 692.61 billion. It is predicted to garner US$ 1,225.24 billion by 2030 to expand at 7.4% CAGR between 2022 and 2030.
Based on country, the North America antibody discovery market is categorized into the US, Canada, and Mexico. Our regional analysis states that the US captured 84.9% share of North America antibody discovery market in 2022. It was assessed at US$ 1,102.72 billion in 2022 and is likely to hit US$ 1,903.58 billion by 2030, registering a CAGR of 7.1% during 2022-2030.
Key players operating in the North America antibody discovery market are Charles River Laboratories International Inc, Creative Biolabs Inc, Evotec SE, Bruker Cellular Analysis Inc, BioDuro LLC, Sartorius AG, Aragen Life Sciences Ltd, Twist Bioscience Corp, NanoCellect Biomedical Inc, and Biocytogen Pharmaceuticals Beijing Co Ltd, among others.
- In January 2024, Biocytogen Pharmaceuticals Co Ltd launched a new sub-brand, RenBiologics, to represent the company's antibody discovery business division. RenBiologics business will cover out-licensing/co-development of the company's extensive library of fully human antibodies, as well as licensing of RenMice, the company's fully human antibody/TCR discovery platforms.
- In August 2023, Twist Bioscience Corp announced a drug discovery agreement with Ono Pharmaceutical Co Ltd to discover and develop novel antibodies for the treatment of autoimmune diseases.
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com